AstraZeneca(AZN) Prnewswire·2025-02-20 15:24Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against AstraZeneca PLC due to allegations of securities law violations related to insurance fraud in China, which has led to significant legal exposure and a decline in stock value [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in AstraZeneca between February 23, 2022, and December 17, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against AstraZeneca, with a deadline of February 21, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that AstraZeneca and its executives made false or misleading statements and failed to disclose significant legal risks associated with insurance fraud in China [4]. Group 2: Impact on Stock Performance - Following the announcement on October 30, 2024, regarding the cooperation of Leon Wang, AstraZeneca's China President, with Chinese authorities, the company's American Depositary Shares (ADS) fell by 3.1% [5]. - An article published on November 5, 2024, reported that dozens of senior executives at AstraZeneca China were implicated in an insurance fraud case, leading to a further decline of 7.2% in AstraZeneca's ADS [6]. Group 3: Whistleblower and Investor Information - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, shareholders, and others regarding AstraZeneca's conduct [8].